Tracking CRE

CDC is working to better understand the true number of infections caused by these organisms in the US. Unlike other drug-resistant infections, CRE infections are not a nationally reportable or notifiable disease. Therefore, there is not a requirement to report to CDC. CDC collects information on CRE from two surveillance systems:
Emerging Infections Program (EIP) –
Healthcare Associated Infections Community Interface (HAIC) uses 10 sites across the country to determine which patients and community members have or are at risk for CRE and Acinetobacter.

Multi-site resistant Gram-negative Surveillance Initiative (MuGSI)

National Healthcare Safety Network (NHSN) – tracks healthcare–associated infections of more than 9,000 facilities nationwide.

It is important to note that CRE, unlike other drug-resistant infections such as VRSA, are not a nationally reportable or notifiable disease. Therefore, there is not a requirement to report to CDC and therefore we may not know the true number of infections caused by these organisms in the US (only those voluntarily reported to CDC).
Below is a map showing states with carbapenemase-producing CRE confirmed by CDC.

Carbapenemase-producing CRE in the United States

Carbapenem-Resistant Enterobacteriaceae map

States with confirmed CRE cases caused by the KPC enzyme

Alabama
Arizona
Arkansas
California (CRE caused by the NDM-1 enzyme, VIM or IMP enzyme)
Colorado
Delaware
Florida
Georgia
Illinois (CRE caused by the NDM-1 enzyme)
Indiana
Iowa
Kentucky
Louisiana
Maryland (CRE caused by the NDM-1 enzyme)
Massachusetts (CRE caused by the NDM-1 enzyme)
Michigan
Minnesota
Mississippi
Missouri

Montana
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oregon
Pennsylvania
Puerto Rico
South Carolina
Tennessee
Texas
Utah
Virginia (CRE caused by the NDM-1 enzyme)
West Virginia
Wisconsin
Wyoming